The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion

Frontiers in Physiology

Volumn 3 JUL, Issue , 2012, Pages

  Evans, Anthony ^a   Costello, Eithne ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Inflammation; Macrophages; Mast cells; Myeloid derived suppressor cells; Neutrophils; Regulatory t cells; Stroma; T helper cells

Indexed keywords

EID: 84866450512     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2012.00270     Document Type: Short Survey

References (76)

1. Abbas, A. K., Murphy, K. M., and Sher, A. (1996). Functional diversity of helper T lymphocytes. Nature 383, 787-793.
2. Angst, E., Reber, H. A., Hines, O. J., and Eibl, G. (2008). Mononuclear cell-derived interleukin-1 beta confers chemoresistance in pancreatic cancer cells by upregulation of cyclooxygenase-2. Surgery 144, 57-65.
3. Beatty, G. L., Chiorean, E. G., Fishman, M. P., Saboury, B., Teitelbaum, U. R., Sun, W., Huhn, R. D., Song, W., Li, D., Sharp, L. L., Torigian, D. A., O'dwyer, P. J., and Vonderheide, R. H. (2011). CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science 331, 1612-1616.
4. Bellone, G., Turletti, A., Artusio, E., Mareschi, K., Carbone, A., Tibaudi, D., Robecchi, A., Emanuelli, G., and Rodeck, U. (1999). Tumor-associated transforming growth factor-β and interleukin-10 contribute to a systemic Th2 immune phenotype in pancreatic carcinoma patients. Am. J. Pathol. 155, 537-547.
5. Bhatti, I., Peacock, O., Lloyd, G., Larvin, M., and Hall, R. I. (2010). Preoperative hematologic mark ers as independent predictors of prognosis in resected pan creatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am. I Surg. 200, 197-203.
6. Cai, S. W., Yang, S. Z., Gao, J., Pan, K., Chen, J. Y., Wang, Y. L., Wei, L. X., and Dong, J. H. (2011). Prognostic significance of mast cell count following curative resection for pancreatic ductal adenocarcinoma. Surgery 149, 576-584.
7. Campbell, A. S., Albo, D., Kimsey, T. F., White, S. L., and Wang, T. N. (2005). Macrophage inflammatory protein-3α promotes pancreatic cancer cell invasion. J. Surg. Res. 123, 96-101.
8. Chang, D. Z., Ma, Y., Ji, B. A., Wang, H. M., Deng, D. F., Liu, Y., Abbruzzese, J. L., Liu, Y J., Logsdon, C. D., and Hwu, P. (2011). Mast cells in tumor microenvironment promotes the in vivo growth of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 17, 7015-7023.
9. Cho, H., Hur, H., Kim, S., Kim, S., Kim, J., Kim, Y., and Lee, K. (2009). Pre-treatment neutrophil to lymphocyte ratio is elevated in epithelial ovarian cancer and predicts survival after treatment. Cancer Immunol. Immunother. 58, 15-23.
10. Clark, C. E., Hingorani, S. R., Mick, R., Combs, C., Tuveson, D. A., and Vonderheide, R. H. (2007). Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 67, 9518-9527.
11. Coussens, L. M., and Werb, Z. (2002). Inflammation and cancer. Nature 420, 860-867.
12. de Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga, M., Di Carlo, V., Doglioni, C., and Protti, M. P. (2011). Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J. Exp. Med. 208, 469-478.
13. De Visser, K. E., Eichten, A., and Coussens, L. M. (2006). Paradoxical roles of the immune system during cancer development. Nat. Rev. Cancer 6, 24-37.
14. Dineen, S. P., Lynn, K. D., Holloway, S. E., Miller, A. F., Sullivan, J. P., Shames, D. S., Beck, A. W., Barnett, C. C., Fleming, J. B., and Brekken, R. A. (2008). Vascular endothelial growth factor receptor 2 mediates macrophage infiltration into ortho-topic pancreatic tumors in mice. Cancer Res. 68, 4340-4346.
15. Esposito, I., Menicagli, M., Funel, N., Bergmann, F., Boggi, U., Mosca, F., Bevilacqua, G., and Campani, D. (2004). Inflammatory cells con tribute to the generation of an angiogenic phenotype in pancre atic ductal adenocarcinoma. J. Clin. Pathol. 57, 630-636.
16. Farrow, B., Albo, D., and Berger, D. H. (2008). The role of the tumor microenvironment in the progression of pancreatic cancer. J. Surg. Res. 149,319-328.
17. Fridman, W. H., Galon, J., Pages, F., Tartour, E., Sautes-Fridman, C., and Kroemer, G. (2011). Prognostic and predictive impact of intra- and per-itumoral immune infiltrates. Cancer Res. 71, 5601-5605.
18. Gabitass, R. F., Annels, N. E., Stocken, D. D., Pandha, H. A., and Middleton, G. W. (2011). Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 60, 1419-1430.
19. Gaça, M. D. A., Zhou, X., and Benyon, R. C. (2002). Regulation of hepatic stellate cell proliferation and collagen synthesis by proteinase-activated receptors. J. Hepatol. 36, 362-369.
20. Gilfillan, A. M., and Beaven, M. A. (2011). Regulation of mast cell responses in health and disease. Crit Rev. Immunol. 31, 475-529.
21. Gomez, D., Farid, S., Malik, H., Young, A., Toogood, G., Lodge, J., and Prasad, K. (2008). Preoperative neutrophil-to-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. WorldJ. Surg. 32, 1757-1762.
22. Grippo, P. J., and Tuveson, D. A. (2010). Deploying mouse models of pancreatic cancer for chemoprevention studies. Cancer Prev. Res. (Phila.) 3, 1382-1387.
23. Guerra, C., Collado, M., Navas, C., Schuhmacher, A. J., Hernandez-Porras, I., Canamero, M., Rodriguez-Justo, M., Serrano, M., and Barbacid, M. (2011). Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence. Cancer Cell 19, 728-739.
24. Guerra, C., Schuhmacher, A. J., Canamero, M., Grippo, P. J., Verdaguer, L., Perez-Gallego, L., Dubus, P., Sandgren, E. P., and Barbacid, M. (2007). Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 11, 291-302.
25. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
26. Hiraoka, N., Onozato, K., Kosuge, T., and Hirohashi, S. (2006). Prevalence of FOXP3(+) regulatory T cells increases during the progression of pancreatic ductal adenocarcinorna and its premalignant lesions. Clin. Cancer Res. 12, 5423-5434.
27. Hiraoka, N., Yamazaki-Itoh, R., Ino, Y., Mizuguchi, Y., Yamada, T., Hirohashi, S., and Kanai, Y (2011). CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraep-ithelial stages of human pancreatic carcinogenesis. Gastroenterology 140, 310-321.
28. Hwang, R. F., Moore, T., Arumugam, T., Ramachandran, V., Amos, K. D., Rivera, A., Ji, B., Evans, D. B., and Logsdon, C. D. (2008). Cancer-associated stromal fibroblasts promote pancreatic tumor progression. Cancer Res. 68, 918-926.
29. Kimsey, T. F., Campbell, A. S., Albo, D., and Wang, T. N. (2004). Co-localization of macrophage inflammatory protein-3alpha (Mip-3alpha) and its receptor, CCR6, promotes pancreatic cancer cell invasion. Cancer J. 10, 374-380.
30. Kleeff, J., Kusama, T., Rossi, D. L., Ishiwata, T., Maruyama, H., Friess, H., Büchler, M. W., Zlotnik, A., and Korc, M. (1999). Detection and localization of MIP-3α/LARC/exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int. J. Cancer 81, 650-657.
31. Koido, S., Homma, S., Takahara, A., Namiki, Y., Tsukinaga, S., Mitobe, J., Odahara, S., Yukawa, T., Matsudaira, H., Nagatsuma, K., Uchiyama, K., Satoh, K., Ito, M., Komita, H., Arakawa, H., Ohkusa, T., Gong, J. L., and Tajiri, H. (2011). Current immunother-apeutic approaches in pancreatic cancer. Clin. Dev. Immunol. 2011, 15.
32. Korc, M. (2007). Pancreatic cancer-associated stroma production. Am. J. Surg. 194, S84-S86.
33. Kumar, V., and Sharma, A. (2010). Neutrophils: cinderella of innate immune system. Int. Immunopharmacol. 10, 1325-1334.
34. Kurahara, H., Shinchi, H., Mataki, Y., Maemura, K., Noma, H., Kubo, F., Sakoda, M., Ueno, S., Natsugoe, S., and Takao, S. (2011). Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. J. Surg. Res. 167, e211-e219.
35. + T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J. Immunol. 172, 989-999.
36. Lowenfels, A. B., Maisonneuve, P., Cavallini, G., Ammann, R. W., Lankisch, P. G., Andersen, J. R., Dimagno, E. P., Andren-Sandberg, A., and Domellof, L. (1993). Pancreatitis and the risk of pancreatic cancer. N. Engl. J. Med. 328, 1433-1437.
37. Lu, T. Y., Ramakrishnan, R., Altiok, S., Youn, J. I., Chong, P. Y., Celis, E., Pisarev, V., Sherman, S., Sporn, M. B., and Gabrilovich, D. (2011). Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J. Clin. Invest. 121, 4015-4029.
38. Mantovani, A., Cassatella, M. A., Costantini, C., and Jaillon, S. (2011). Neutrophils in the activation and regulation of innate and adaptive immunity. Nat. Rev. Immunol. 11, 519-531.
39. Masamune, A., Watanabe, T., Kikuta, K., Satoh, K., Kanno, A., and Shimosegawa, T. (2010). Nuclear expression of interleukin-33 in pancreatic stellate cells. Am. J. Physiol Gastrointest. Liver Physiol. 299, G821-G832.
40. McKay, C. J., Glen, P., and McMillan, D. C. (2008). Chronic inflammation and pancreatic cancer. Best Pract. Res. Clin. Gastroenterol. 22, 65-73.
41. Menetrier-Caux, C., Curiel, T., Faget, J., Manuel, M., Caux, C., and Zou, W. (2012). Targeting regulatory T cells. Target. Oncol. 7, 15-28.
42. Moo-Young, T. A., Larson, J. W., Belt, B. A., Tan, M. C., Hawkins, W. G., Eberlein, T. J., Goedegebuure, P. S., and Linehan, D. C. (2009). Tumor-derived TGF-beta mediates conversion of CD4(+)Foxp3(+) reg ulatory T cells in a murine model of pancreas cancer. J. Immunother. 32, 12-21.
43. Morris, J. P. T., Cano, D. A., Sekine, S., Wang, S. C., and Hebrok, M. (2010). Beta-catenin blocks Kras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice. J. Clin. Invest. 120, 508-520.
44. Neesse, A., Michl, P., Frese, K. K., Feig, C., Cook, N., Jacobetz, M. A., Lolkema, M. P., Buchholz, M., Olive, K. P., Gress, T. M., and Tuveson, D. A. (2010). Stromal biology and therapy in pancreatic cancer. Gut. 60, 861-868.
45. Norrby, K. (2002). Mast cells and angiogenesis. APMIS 110, 355-371.
46. + T cells. Science 327, 1098-1102.
47. Ochando, J. C., and Chen, S. H. (2012). Myeloid-derived suppressor cells in transplantation and cancer. Immunol Res. doi: 10.1007/s12026-012-8335-1. [Epub ahead of print].
48. + T helper 2 cells-microbial triggers, differentiation requirements and effector functions. Immunology 134, 368-377.
49. Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., Mcintyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., Frese, K. K., Denicola, G., Feig, C., Combs, C., Winter, S. P., Ireland-Zecchini, H., Reichelt, S., Howat, W. J., Chang, A., Dhara, M., Wang, L., Ruckert, F., Grutzmann, R., Pilarsky, C., Izeradjene, K., Hingorani, S. R., Huang, P., Davies, S. E., Plunkett, W., Egorin, M., Hruban, R. H., Whitebread, N., Mcgovern, K., Adams, J., Iacobuzio-Donahue, C., Griffiths, J., and Tuveson, D. A. (2009). Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461.
50. Ostrand-Rosenberg, S., and Sinha, P. (2009). Myeloid-derived suppressor cells: linking inflammation and cancer.J. Immunol. 182, 4499-4506.
51. Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., and Clements, V. K. (2012). Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin. Cancer Biol. 22, 275-281.
52. Pages, F., Galon, J., Dieu-Nosjean, M. C., Tartour, E., Sautes-Fridman, C., and Fridman, W. H. (2010). Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093-1102.
53. Pilon-Thomas, S., Nelson, N., Vohra, N., Jerald, M., Pendleton, L., Szekeres, K., and Ghansah, T. (2011). Murine pancreatic adenocarcinoma dampens SHIP-1 expression and alters MDSC homeostasis and function. PLoS ONE 6:e27729. doi: 10.1371/journal.pone.0027729
54. Polyak, K., Haviv, I., and Campbell, I. G. (2009). Co-evolution of tumor cells and their microenvironment. Trends Genet. 25, 30-38.
55. Puolakkainen, P. A., Brekken, R. A., Muneer, S., and Sage, E. H. (2004). Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. Mol. Cancer Res. 2, 215-224.
56. Tumor-infiltrating neu-trophils in pancreatic neoplasia
57. Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, E, Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., Leach, S. D., and Stanger, B. Z. (2012). EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361.
58. Ribatti, D., and Crivellato, E. (2011). Mast cells, angiogenesis and cancer. Adv. Exp. Med. Biol. 716, 270-288.
59. Roxburgh, C. S. D., and McMillan, D. C. (2011). The role of the in situ local inflammatory response in predicting recurrence and survival in patients with primary operable colorectal cancer. Cancer Treat. Rev. 38,451-466.
60. Ruffell, B., Affara, N. I., and Coussens, L. M. (2012). Differential macrophage programming in the tumor microenvironment. Trends Immunol. 33, 119-126.
61. Sarraf, K. M., Belcher, E., Raevsky, E., Nicholson, A. G., Goldstraw, P., and Lim, E. (2009). Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 137, 425-428.
62. Schmidt, A., Oberle, N., and Krammer, P. H. (2012). Molecular mechanisms of treg-mediated T cell suppression. Front. Immunol. 3:51. doi: 10.3389/fimmu.2012.00051
63. Stokes, J. B., Adair, S. J., Slack-Davis, J. K., Walters, D. M., Tilghman, R. W., Hershey, E. D., Lowrey, B., Thomas, K. S., Bouton, A. H., Hwang, R. F., Stelow, E. B., Parsons, J. T., and Bauer, T. W. (2011). Inhibition of focal adhesion kinase by PF-562, 271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol. Cancer Ther. 10, 2135-2145.
64. Strouch, M. J., Cheon, E. C., Salabat, M. R., Krantz, S. B., Gounaris, E., Melstrom, L. G., Dangi-Garimella, S., Wang, E., Munshi, H. G., Khazaie, K., and Bentrem, D. J. (2010). Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin. Can. Res. 16, 2257-2265.
65. Tan, M. C. B., Goedegebuure, P. S., Belt, B. A., Flaherty, B., Sankpal, N., Gillanders, W. E., Eberlein, T. J., Hsieh, C.-S., and Linehan, D. C. (2009). Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J. Immunol. 182, 1746-1755.
66. + T cell immunity is impaired in pancreatic carcinoma patients. J. Immunol. 181, 6595-6603.
67. Vanneman, M., and Dranoff, G. (2012). Combining immunother-apy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251.
68. Vitone, L. J., Greenhalf, W., Howes, N. R., and Neoptolemos, J. P. (2005). Hereditary pancreatitis and secondary screening for early pancreatic cancer. Rocz. Akad. Med. Bialymst. 50, 73-84.
69. Von Bernstorff, W., Voss, M., Freichel, S., Schmid, A., Vogel, I., Johnk, C., Henne-Bruns, D., Kremer, B., and Kalthoff, H. (2001). Systemic and local immunosuppression in pancreatic cancer patients. Clin. Cancer Res. 7, 925S-932S.
70. Vonlaufen, A., Joshi, S., Qu, C., Phillips, P. A., Xu, Z., Parker, N. R., Toi, C. S., Pirola, R. C., Wilson, J. S., Goldstein, D., and Apte, M. V. (2008). Pancreatic stellate cells: partners in crime with pancreatic cancer cells. Cancer Res. 68, 2085-2093.
71. Wachsmann, M. B., Pop, L. M., and Vitetta, E. S. (2012). Pancreatic duc-tal adenocarcinoma: a review of immunologic aspects. J. Invest. Med. 60, 643-663.
72. Walsh, S. R., Cook, E. J., Goulder, F., Justin, T. A., and Keeling, N. J. (2005). Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J. Surg. Oncol. 91, 181-184.
73. Wang, D. S., Luo, H. Y., Qiu, M. Z., Wang, Z. Q., Zhang, D. S., Wang, F. H., Li, Y. H., and Xu, R. H. (2012). Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med. Oncol. doi: 10.1007/s12032-012-0226-8. [Epub ahead of print].
74. Whiteside, T. L. (2008). The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-5912.
75. Xu, D., Jiang, H. R., Kewin, P., Li, Y., Mu, R., Fraser, A. R., Pitman, N., Kurowska-Stolarska, M., McKenzie, A. N. J., McInnes, I. B., and Liew, F. Y (2008). IL-33 exacerbates antigen-induced arthritis by activating mast cells. Proc. Natl. Acad. Sci. U.S.A. 105, 10913-10918.
76. Yamasaki, A., Kameda, C., Xu, R., Tanaka, H., Tasaka, T., Chikazawa, N., Suzuki, H., Morisaki, T., Kubo, M., Onishi, H., Tanaka, M., and Katano, M. (2010). Nuclear factor kappaB-activated monocytes contribute to pancreatic cancer progression through the production of Shh. Cancer Immunol. Immunother. 59, 675-686.